• We report herein an electrochemical analysis of the interact

  2022-03-31

  

  We report herein an electrochemical analysis of the interaction between L1 and sGC, where conventional solution phase voltammetry is combined with a novel technique, the voltammetry of microparticles (VMP), in order to obtain mechanistic information on the deactivation of sGC by L1. The VMP is a sol

• Activity of compound in rat brain tissue highlights the pote

  2022-03-31

  

  Activity of compound 10 in rat 2750 tissue highlights the potential to use this new class of allosteric sGC inhibitors to study the role of the NO—sGC—cGMP signalling pathway in the brain. Reducing amounts of cGMP in cells would have implications in downstream signalling proteins, such as cGMP-depe

• A motivation for this study is the ability

  2022-03-31

  

  A motivation for this study is the ability of PGD2 to inhibit hair lengthening (). Here we demonstrate that PGD2 also inhibits hair regeneration after wounding. Thus, PGD2 and Gpr44 inhibition of the hair follicle occurs in multiple contexts and may be exploited in future therapies. Pharmaceutical c

• The rat model was validated with another agonist of GPR

  2022-03-31

  

  The rat model was validated with another agonist of GPR109A, acipimox. Acipimox has been shown to induce vasodilatation in man, by a mechanism dependent on the release of vasodilator prostaglandins (Edlund et al., 1990, Pontiroli et al., 1992). Acipimox is a weaker agonist of the GPR109A receptor (L

• br Methods and materials br Acknowledgements The authors tha

  2022-03-31

  

  Methods and materials Acknowledgements The authors thank the NIH AIDS Reagent Program for providing the materials and reagents. The HIV-1 1084i envelope gene was a generous gift from Dr. Charles Wood. This work was supported in part by grants to S.-H. X. from the Bill and Melinda Gates Foundat

• br AUTHOR CONTRIBUTIONS br ACKNOWLEDGMENTS br

  2022-03-31

  

  AUTHOR CONTRIBUTIONS ACKNOWLEDGMENTS Introduction Chronic neuropathic pain is a common symptom in patients with human immunodeficiency virus (HIV)-1 infection. Glycoprotein 120 (gp120) is an HIV-1 protein that can cause pain behaviors in animal models (Hao, 2013, Nasirinezhad et al., 2015,

• br Significant efforts are currently focused on non

  2022-03-31

  

  Significant efforts are currently focused on non-dopaminergic strategies to address the unmet medical needs in schizophrenia, and targeting -methyl--aspartate (NMDA) bradykinin receptor antagonist hypofunction has garnered a great deal of attention., , Elevation of synaptic glycine levels near N

• FPG had no consistent activity in reducing G T

  2022-03-31

  

  FPG-2 had no consistent activity in reducing G→T transversions. Gao and Murphy [2] earlier reported that FPG-2 had a limited amount of activity in vitro on depurinated, UV-treated, and methylene-blue-treated DNA (but not on 8-oxo-G-containing oligonucleotides). FPG-2 contains the N-terminal domain a

• In insects structural cuticular proteins CPs play

  2022-03-31

  

  In insects, structural cuticular proteins (CPs) play important roles in determining the diverse physical properties of the cuticle, depending on developmental stages, as well as different body regions, as a result of interactions with other CPs and the structural biopolymer chitin [4]. Many studies

• In this study we find that DH

  2022-03-31

  

  In this study, we find that DH-CBD induces analgesic effects on inflammatory but not acute pain and the Antagonist G receptor level of spinal α1 GlyRs increased after CFA paw injection. These results suggest that GlyR α1 is only involved in chronic pain. A possible explanation is that once the expr

• br Membrane transporters as a novel therapeutic target

  2022-03-31

  

  Membrane transporters as a novel therapeutic target in pediatric TBI The concept of targeting membrane transporters began with identifying a neuroprotective drug and a corresponding transporter inhibitor. Somewhat serendipitously, we discovered that N-acetylcysteine (NAC), a cysteine donor for GS

• Genetic disruption or pharmacologic inhibition of the hepati

  2022-03-31

  

  Genetic disruption or pharmacologic inhibition of the hepatic glucagon pathway has invariably been shown to increase pancreatic α cell mass. This has been observed in glucagon receptor (GCGR) knockout (Gcgr−/−) mice (Gelling et al., 2003), glucagon knockout mice (Hayashi et al., 2009), prohormone co

• Nano biocatalyst prepared by assembling an enzyme on nanomat

  2022-03-30

  

  Nano-biocatalyst, prepared by assembling an enzyme on nanomaterial (NM) carriers is an emerging innovation in the field of nanobiotechnology. Some of the advantages of using NM as supports in Angiotensin 1/2 (1-5) to conventional porous supports are effective enzyme loading due to large surface are

• The optimum parameter sets were detected by the highest

  2022-03-30

  

  The optimum parameter sets were detected by the highest J-statistic for the training set and applied to the test set for evaluation. J-statistics obtained from the test set is reported at Table 2 along with respective parameters. We also applied QP, G4H and PQSF methods, in order to compare the pre

• br The bile acid farnesoid X

  2022-03-30

  

  The “bile acid” farnesoid X receptor (FXR) The Farnesoid X Receptor (FXR) is a ligand-activated nuclear receptor belonging to the Nuclear Receptor superfamily of transcription factors exploiting various crucial functions in mammalian physiology, including reproduction, development and metabolism

15555 records 453/1037 page Previous Next First page 上5页 451452453454455 下5页 Last page